IRIS
CASTIGLIONE, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.195
AS - Asia 7.076
EU - Europa 5.897
SA - Sud America 1.573
AF - Africa 186
Continente sconosciuto - Info sul continente non disponibili 172
OC - Oceania 17
Totale 29.116
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.362
SG - Singapore 2.548
IT - Italia 2.024
CN - Cina 1.861
RU - Federazione Russa 1.689
BR - Brasile 1.242
VN - Vietnam 885
HK - Hong Kong 491
BD - Bangladesh 482
GB - Regno Unito 453
CA - Canada 448
DE - Germania 331
FR - Francia 260
FI - Finlandia 235
SE - Svezia 182
IN - India 173
IE - Irlanda 146
MX - Messico 135
TR - Turchia 129
NL - Olanda 120
AR - Argentina 106
PL - Polonia 88
UA - Ucraina 87
ID - Indonesia 77
ES - Italia 68
IQ - Iraq 66
ZA - Sudafrica 66
EC - Ecuador 59
PK - Pakistan 58
JP - Giappone 46
AT - Austria 45
IL - Israele 44
CO - Colombia 42
CR - Costa Rica 39
VE - Venezuela 37
AE - Emirati Arabi Uniti 32
SV - El Salvador 32
TT - Trinidad e Tobago 31
GT - Guatemala 27
HN - Honduras 27
LT - Lituania 27
MA - Marocco 27
UZ - Uzbekistan 27
PY - Paraguay 26
MY - Malesia 23
PR - Porto Rico 22
CL - Cile 21
SA - Arabia Saudita 19
JM - Giamaica 18
PE - Perù 18
CW - ???statistics.table.value.countryCode.CW??? 17
EG - Egitto 16
CH - Svizzera 15
RO - Romania 15
KE - Kenya 14
TN - Tunisia 14
AU - Australia 13
BE - Belgio 13
DZ - Algeria 13
NI - Nicaragua 13
PH - Filippine 13
AL - Albania 11
DO - Repubblica Dominicana 11
AZ - Azerbaigian 10
CZ - Repubblica Ceca 10
GP - Guadalupe 10
UY - Uruguay 10
DK - Danimarca 9
JO - Giordania 9
NP - Nepal 9
GR - Grecia 8
MC - Monaco 8
SN - Senegal 8
TH - Thailandia 8
BO - Bolivia 7
MD - Moldavia 7
PA - Panama 7
CI - Costa d'Avorio 6
HU - Ungheria 6
IR - Iran 6
KZ - Kazakistan 6
OM - Oman 6
PT - Portogallo 6
TW - Taiwan 6
AM - Armenia 4
BB - Barbados 4
BG - Bulgaria 4
BH - Bahrain 4
BY - Bielorussia 4
GY - Guiana 4
KR - Corea 4
PS - Palestinian Territory 4
SI - Slovenia 4
AO - Angola 3
EE - Estonia 3
ET - Etiopia 3
LB - Libano 3
LV - Lettonia 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
Totale 28.898
Salva come PNG Salva come JPEG
Città #
Dallas 2.459
Singapore 1.401
Ashburn 1.038
San Jose 1.037
Chicago 881
Los Angeles 702
Beijing 640
Council Bluffs 606
Hong Kong 473
Salt Lake City 397
Moscow 317
Ho Chi Minh City 295
Milan 294
Buffalo 291
New York 272
Tampa 207
Santa Clara 206
Rome 204
Hanoi 197
Chandler 181
Elk Grove Village 171
Phoenix 163
São Paulo 153
Helsinki 151
Dublin 142
The Dalles 136
Boardman 130
Lauterbourg 126
Wilmington 112
Hefei 107
Munich 102
Pisa 102
Montreal 94
Beauharnois 89
Orem 89
Florence 87
Fairfield 84
San Mateo 82
Sterling 81
Houston 76
London 76
Seattle 76
Warsaw 75
Lancaster 73
Toronto 71
Atlanta 67
Istanbul 67
Miami 67
Denver 66
Mexico City 66
Cambridge 65
Frankfurt am Main 64
Naples 60
Amsterdam 59
Poplar 59
Stockholm 54
Brooklyn 53
Dulles 48
Ottawa 46
Chennai 45
Nuremberg 45
Lappeenranta 44
Tokyo 44
Bologna 43
Da Nang 43
Turin 43
Johannesburg 42
Portsmouth 41
Rio de Janeiro 41
Stevenage 38
Detroit 36
Kansas City 36
Palermo 36
Boston 35
Manchester 35
Turku 35
Washington 35
Columbus 34
Tel Aviv 34
Jacksonville 33
Southend 33
Falls Church 32
Hangzhou 32
San José 32
Belo Horizonte 31
Lucca 31
Woodbridge 31
Haiphong 30
Lawrence 30
Figino 29
Genoa 29
Ankara 28
Guangzhou 27
Pittsburgh 27
San Francisco 26
San Salvador 26
Mumbai 25
Paris 25
Guayaquil 24
Porto Alegre 24
Totale 16.977
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.863
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.733
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 752
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 633
A simple echocardiographic score to rule out cardiac amyloidosis 433
A simple echocardiographic score to rule out cardiac amyloidosis 412
[Central apneas and cardiovascular diseases] 358
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 350
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 325
Eligibility for vericiguat in a real‐world, contemporary heart failure population 323
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 321
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 315
RNA-targeting and gene editing therapies for transthyretin amyloidosis 314
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 294
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 291
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 289
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 283
Atrial amyloidosis: mechanisms and clinical manifestations 280
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 280
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 278
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 276
Biomarkers for the diagnosis and management of heart failure: New frontiers 276
Biomarkers for the diagnosis and management of heart failure 274
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 272
Valve disease in cardiac amyloidosis: an echocardiographic score 271
Disease features and management of cardiomyopathies in women 271
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 269
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 268
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 267
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 263
Cardiac magnetic resonance in patients with muscular dystrophies 262
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 260
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 257
Role of Imaging in Cardiomyopathies 255
Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction 255
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 253
Valvular heart disease in patients with cardiac amyloidosis 248
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 243
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 243
Cardiac Amyloidosis: How Its Epidemiology is Changing 242
Cardiovascular disease and COVID-19: les liaisons dangereuses 240
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 240
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 238
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 237
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 236
Cardiac amyloidosis: Innovations in diagnosis and treatment 235
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets 235
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 232
Tissue Characterization in Cardiac Amyloidosis 232
Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis 232
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 232
Molecular autopsy of sudden cardiac death in the genomics era 231
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 230
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 226
Positron emission tomography in cardiac amyloidosis: current evidence and future directions 224
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 221
PET and Cardiac Amyloidosis 218
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 217
Cardiovascular toxicity from therapies for light chain amyloidosis 217
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction 217
Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report 216
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 215
Use of biomarkers to diagnose and manage cardiac amyloidosis 215
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 213
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 210
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week 209
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy 206
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 204
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy 202
Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction 201
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 201
Sex differences in transthyretin cardiac amyloidosis 200
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 198
Pathophysiology of Cardiac Amyloidosis 194
Current and emerging drug targets in heart failure treatment 194
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 192
Obstructive sleep apnea and cardiovascular diseases 190
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond 189
Coronary Artery Anomalies 188
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines 188
Critical Reading of cardiovascular trials with neutral or negative results 183
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? 183
Treatment of cardiac transthyretin amyloidosis: an update 183
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 182
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 181
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 179
What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas 176
Safety and Efficacy of Amiodarone in a Patient With COVID-19 172
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? 169
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study 166
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis 164
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? 163
The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? 163
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is 157
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 156
Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician 147
Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry 145
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 144
Statin therapy in COVID-19 infection 144
The unbearable underreporting of comorbidities in heart failure clinical trials 143
Totale 27.267
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.726
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.726
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022415 0 0 0 39 25 62 45 94 58 50 7 35
2022/2023563 33 61 23 50 58 71 23 49 103 22 51 19
2023/2024756 43 15 140 74 47 65 53 31 27 47 31 183
2024/20258.175 51 97 231 132 304 256 611 1.146 434 1.070 2.215 1.628
2025/202615.832 840 2.010 2.133 2.037 1.493 1.030 1.399 760 1.081 1.087 1.069 893
2026/20272.790 411 482 923 974 0 0 0 0 0 0 0 0
Totale 29.116